3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Head & Neck
4
Dermatologic
1
Conditions
Uveal Melanoma
2
Melanoma
2
Waldenstrom Macroglobulinemia
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Neoplasm Metastasis
1
Lymphoma, T-Cell, Peripheral
1
Lymphoma, T-Cell, Cutaneous
1
Lymphoma, Non-Hodgkin
1
Lymphoma, Mantle-Cell
1
Lymphoma, Large B-Cell, Diffuse
1
Lymphoma, Follicular
1
Lymphoma, B-Cell, Marginal Zone
1
Lymphoma
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Leukemia
1
Hodgkin Disease
1
Head and Neck Neoplasms
1
Burkitt Lymphoma
1
Interventions
pembrolizumab
24
Nivolumab
9
atezolizumab
8
Drug Therapy
6
cemiplimab
5
Immune Checkpoint Inhibitors
5
fludarabine
4
Radiotherapy
4
Paclitaxel
4
Interleukin-2
4
Cyclophosphamide
4
Docetaxel
3
fludarabine phosphate
2
epacadostat
2
durvalumab
2
aldesleukin
2
Taxes
2
Radiosurgery
2
Radiation
2
Patient Reported Outcome Measures
2
Oncolytic Virotherapy
2
Ipilimumab
2
Immunotherapy
2
Gemcitabine
2
Filgrastim
2
Cisplatin
2
Cetuximab
2
Carboplatin
2
vocimagene amiretrorepvec
1
venetoclax
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Head and Neck Neoplasms
×
Valproic Acid
×
Dermatologic
×
Clear all
NCT04729543
2023-12-04
MC2TCR
Erasmus Medical Center
Phase 1/2
Recruiting
20 enrolled